<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 3: Metabolic & Cardiovascular Risk Screening | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: transparent;
 border: none;
 border-radius: 0;
 padding: 0;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border: none;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #f3f4f6;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

.welcome-box h3 {
 color: #92400e;
 font-size: 18px;
 font-weight: 700;
 margin-bottom: 12px;
}

.welcome-box p {
 margin: 0;
 font-size: 16px;
 color: #44403c;
 line-height: 1.7;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #7e22ce;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
 margin: 0;
 padding: 0;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #4c1d95;
 border-bottom: 1px solid rgba(167, 139, 250, 0.2);
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #7c3aed;
 font-weight: 700;
}

/* HIGHLIGHT */
.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 6px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

p {
 font-size: 17px;
 line-height: 1.85;
 color: #374151;
 margin-bottom: 20px;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.case-study-icon {
 width: 48px;
 height: 48px;
 background: rgba(255, 255, 255, 0.2);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
}

.case-study-header .title {
 color: white;
 font-weight: 700;
 font-size: 16px;
 margin: 0;
}

.case-study-content {
 padding: 28px;
}

/* COACH TIP BOX */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip::before {
 content: 'üí°';
 position: absolute;
 top: -12px;
 left: 24px;
 background: white;
 padding: 4px 8px;
 border-radius: 8px;
 font-size: 20px;
 box-shadow: 0 2px 8px rgba(0,0,0,0.08);
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* DATA TABLE */
.data-table { width: 100%; border-collapse: collapse; margin: 25px 0; font-size: 15px; }
.data-table th { background: #722F37; color: white; padding: 12px 15px; text-align: left; }
.data-table td { padding: 12px 15px; border-bottom: 1px solid #e5e7eb; }
.data-table tr:nth-child(even) { background: #f9fafb; }

/* CHECK YOUR UNDERSTANDING - MANDATORY STYLE */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}
.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}
.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}
.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}
.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* TAKEAWAYS BOX - MANDATORY STYLE */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}
.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}
.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}
.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES BOX */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}
.references-box ol {
 list-style: none;
 padding: 0;
 counter-reset: ref-counter;
}
.references-box li {
 counter-increment: ref-counter;
 padding: 12px 16px 12px 48px;
 position: relative;
 font-size: 14px;
 color: #475569;
 background: white;
 border-radius: 8px;
 margin-bottom: 8px;
 border: 1px solid #e5e7eb;
}
.references-box li::before {
 content: counter(ref-counter);
 position: absolute;
 left: 16px;
 top: 12px;
 width: 22px;
 height: 22px;
 background: #722F37;
 color: white;
 border-radius: 50%;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
}

@media (max-width: 768px) {
 .lesson-title { font-size: 28px; }
 .toc-list { grid-template-columns: 1fr; }
}
 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 20: Assessment Tools</span>
 <h1 class="lesson-title">Metabolic & Cardiovascular Risk Screening</h1>
 <div class="lesson-meta">
 <span class="meta-badge">Lesson 3 of 8</span>
 <span class="meta-badge">‚è±Ô∏è 14 min read</span>
 <span class="meta-badge">üí° Clinical Assessment</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Verified Credential</div>
 <div class="title">AccrediPro Standards Institute‚Ñ¢ Certified Assessment Protocols</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <span class="toc-label">Lesson Navigation</span>
 <ul class="toc-list">
 <li><a href="#homa-ir"><span class="section-num">01</span>HOMA-IR & Insulin Trends</a></li>
 <li><a href="#lipids"><span class="section-num">02</span>Advanced Lipid Fractionation</a></li>
 <li><a href="#bone-markers"><span class="section-num">03</span>Bone Turnover Markers</a></li>
 <li><a href="#inflammation"><span class="section-num">04</span>hs-CRP & IL-6 Dynamics</a></li>
 <li><a href="#vascular"><span class="section-num">05</span>Arterial Stiffness Assessment</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="welcome-box">
 <h3>Building the "Evolve" Foundation</h3>
 <p>In the previous lesson, we mastered hormonal mapping via DUTCH and saliva testing. Now, we shift our focus to the <span class="highlight">metabolic and cardiovascular health</span> of the midlife woman. As estrogen declines, her risk profile shifts dramatically. Standard labs often miss the early warning signs of the "Menopausal Metabolic Shift." This lesson provides the advanced screening tools to protect her heart and bones for decades to come.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <span class="box-label">Learning Objectives</span>
 <ul>
 <li>Calculate and interpret HOMA-IR to detect insulin resistance before glucose elevations occur.</li>
 <li>Analyze advanced lipid markers including ApoB, Lp(a), and LDL particle size in the context of estrogen deficiency.</li>
 <li>Identify bone turnover markers (NTx and P1NP) as early predictors of bone loss prior to DEXA changes.</li>
 <li>Correlate hs-CRP and IL-6 levels with vasomotor symptom severity and cardiovascular risk.</li>
 <li>Evaluate blood pressure variability and arterial stiffness as critical markers for the 'Evolve' stage.</li>
 </ul>
 </div>

 <h2 id="homa-ir">Calculating HOMA-IR: Detecting the Silent Shift</h2>
 <p>In conventional medicine, a woman is often told her "blood sugar is fine" until her Fasting Glucose exceeds 100 mg/dL or her HbA1c reaches 5.7%. However, the <span class="highlight">estrogen decline</span> of perimenopause often triggers a compensatory rise in insulin long before glucose begins to drift. By the time glucose is elevated, significant metabolic damage may have already occurred.</p>

 <p>The <strong>HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)</strong> is a superior screening tool. It looks at the relationship between fasting insulin and fasting glucose to determine how hard the pancreas is working to maintain stability.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: The Formula</span>
 <p>You can calculate HOMA-IR yourself using this simple formula: <strong>(Fasting Insulin [¬µIU/mL] √ó Fasting Glucose [mg/dL]) / 405</strong>. An optimal score for a midlife woman is <strong>&lt; 1.5</strong>. Anything above 2.0 indicates significant insulin resistance, even if her glucose is "normal."</p>
 </div>

 <table class="data-table">
 <thead>
 <tr>
 <th>Marker</th>
 <th>Conventional "Normal"</th>
 <th>P.H.A.S.E. Optimal Range</th>
 <th>Significance in Menopause</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td>Fasting Insulin</td>
 <td>2.0 - 24.9 ¬µIU/mL</td>
 <td>2.0 - 6.0 ¬µIU/mL</td>
 <td>Early marker of metabolic dysfunction.</td>
 </tr>
 <tr>
 <td>HOMA-IR</td>
 <td>Not usually calculated</td>
 <td>&lt; 1.5</td>
 <td>Identifies "hidden" insulin resistance.</td>
 </tr>
 <tr>
 <td>Triglyceride/HDL Ratio</td>
 <td>&lt; 3.0</td>
 <td>&lt; 1.5</td>
 <td>Strong predictor of insulin particle size.</td>
 </tr>
 </tbody>
 </table>

 <h2 id="lipids">Advanced Lipid Fractionation: Beyond Total Cholesterol</h2>
 <p>Estrogen is cardioprotective; it helps maintain high levels of HDL and keeps LDL particles large and buoyant. As estrogen levels drop, many women see a 10-20% increase in LDL-C. However, the <em>type</em> of particles matters more than the total number.</p>

 <h3>The Significance of ApoB and Lp(a)</h3>
 <p><strong>Apolipoprotein B (ApoB)</strong> represents the total number of atherogenic (plaque-forming) particles. Unlike LDL-C, which measures the <em>weight</em> of cholesterol, ApoB measures the <em>count</em> of the dangerous particles. A woman can have "normal" LDL-C but a very high ApoB, putting her at high risk.</p>

 <p><strong>Lipoprotein(a) [Lp(a)]</strong> is a genetically determined marker that often increases during the menopause transition. High Lp(a) makes the blood "stickier" and significantly increases the risk of stroke and heart attack, regardless of lifestyle. Screening this once in a woman's lifetime‚Äîespecially during perimenopause‚Äîis critical.</p>

 <!-- Case Study 1 -->
 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">üë©‚Äç‚öïÔ∏è</div>
 <div>
 <p class="title">Case Study: The "Healthy" Nurse</p>
 </div>
 </div>
 <div class="case-study-content">
 <p><strong>Client:</strong> Sarah, 51, Nurse. Active, non-smoker, BMI 23.</p>
 <p><strong>Presenting Symptoms:</strong> Increasing "brain fog" and sudden onset of high blood pressure (145/92).</p>
 <p><strong>Conventional Labs:</strong> LDL-C 125 mg/dL (Borderline), Glucose 92 mg/dL (Normal).</p>
 <p><strong>Advanced Screening:</strong> ApoB was in the 95th percentile, and her HOMA-IR was 2.8. Despite her healthy appearance, Sarah was in a state of rapid <span class="highlight">vascular aging</span> due to estrogen loss. By identifying these early, we adjusted her P.H.A.S.E. protocol to include strength training and specific fiber goals, stabilizing her markers within 6 months.</p>
 </div>
 </div>

 <h2 id="bone-markers">Bone Turnover Markers: Predicting the Future</h2>
 <p>A DEXA scan is a "snapshot" of what has already happened to the bone. In the first 5 years of menopause, a woman can lose up to <strong>20% of her bone density</strong>. We don't want to wait 2 years between DEXA scans to see if our interventions are working.</p>

 <p><strong>Bone Turnover Markers (BTMs)</strong> allow us to see the <em>rate</em> of bone change in real-time:</p>
 <ul>
 <li><strong>NTx (N-Telopeptide):</strong> A urinary or blood marker of bone <em>resorption</em> (breakdown). High levels indicate the body is breaking down bone faster than it can build it.</li>
 <li><strong>P1NP (Procollagen type 1 N-terminal propeptide):</strong> A marker of bone <em>formation</em>. This tells us if her "bone-building" machinery is active.</li>
 </ul>

 <p>By monitoring these, a specialist can see within 3 months if a client's nutrition and resistance training program is effectively slowing bone loss.</p>

 <h2 id="inflammation">The Role of hs-CRP and IL-6 in Vasomotor Symptoms</h2>
 <p>Recent research, including data from the <em>Study of Women's Health Across the Nation (SWAN)</em>, has found a direct link between systemic inflammation and the severity of hot flashes. High-sensitivity C-Reactive Protein (hs-CRP) is a marker of "low-grade" systemic inflammation.</p>

 <p>A 2023 meta-analysis found that women with <strong>hs-CRP levels &gt; 2.0 mg/L</strong> were 50% more likely to report frequent and severe vasomotor symptoms (VMS). Chronic inflammation also drives <strong>Interleukin-6 (IL-6)</strong>, which can cross the blood-brain barrier and contribute to "menopause brain" and mood stability issues.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: Practitioner Insight</span>
 <p>When a client has "stubborn" hot flashes that don't respond to standard cooling measures, check her hs-CRP. Often, the "fire" isn't just hormonal‚Äîit's inflammatory. Addressing gut health or food sensitivities can often cool the VMS by lowering systemic inflammation.</p>
 </div>

 <h2 id="vascular">Vascular Health: Arterial Stiffness</h2>
 <p>The loss of estrogen leads to a decrease in <strong>Nitric Oxide</strong> production, the molecule responsible for keeping our arteries flexible. This leads to "arterial stiffness," which causes the top number of blood pressure (systolic) to rise while the bottom number (diastolic) may stay the same or even drop.</p>

 <p>Specialists should look for <strong>Blood Pressure Variability</strong>. If a client's BP is 110/70 in the morning but spikes to 150/90 during stress or after a poor night's sleep, her vascular resilience is declining. This is a hallmark of the 'Evolve' stage (Post-Menopause) where cardiovascular protection becomes the #1 priority.</p>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 
 <div class="question-item">
 <p class="question-text"><strong>1. Why is HOMA-IR more valuable than Fasting Glucose alone during perimenopause?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans1')">Reveal Answer</button>
 <div id="ans1" class="answer-text">HOMA-IR detects insulin resistance by measuring the relationship between insulin and glucose. During the menopause transition, insulin often rises to keep glucose "normal," masking metabolic dysfunction that a standard glucose test would miss.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>2. What does a high NTx marker indicate in a post-menopausal woman?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans2')">Reveal Answer</button>
 <div id="ans2" class="answer-text">A high NTx (N-Telopeptide) indicates an elevated rate of bone resorption (breakdown), suggesting she is losing bone density rapidly, even if her DEXA scan hasn't shown a significant change yet.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>3. Which lipid marker is considered the most accurate count of atherogenic particles?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans3')">Reveal Answer</button>
 <div id="ans3" class="answer-text">Apolipoprotein B (ApoB). It provides a direct count of all potentially plaque-forming particles, making it a better predictor of risk than LDL-C weight in midlife women.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>4. How does hs-CRP relate to hot flashes (VMS)?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans4')">Reveal Answer</button>
 <div id="ans4" class="answer-text">Higher levels of systemic inflammation (measured by hs-CRP) are strongly correlated with increased frequency and severity of vasomotor symptoms.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li><strong>Metabolic Leading Indicators:</strong> Use HOMA-IR (Target &lt; 1.5) and Fasting Insulin (Target 2-6) to identify insulin resistance years before diabetes develops.</li>
 <li><strong>Advanced Lipid Profiling:</strong> Prioritize ApoB and Lp(a) over total cholesterol to accurately assess cardiovascular risk post-estrogen.</li>
 <li><strong>Bone Health Proactivity:</strong> Utilize NTx and P1NP to monitor bone turnover every 3-6 months rather than waiting years for DEXA updates.</li>
 <li><strong>Inflammatory Link:</strong> Address systemic inflammation (hs-CRP) as a primary strategy for managing severe vasomotor symptoms.</li>
 <li><strong>Vascular Resilience:</strong> Monitor systolic blood pressure variability as a sign of decreasing arterial flexibility.</li>
 </ul>
 </div>

 <!-- References -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>El Khoudary, S.R., et al. (2020). "Menopause Transition and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association." <em>Circulation</em>.</li>
 <li>Thurston, R.C., et al. (2023). "Inflammation and Vasomotor Symptoms in the Study of Women's Health Across the Nation (SWAN)." <em>Journal of Clinical Endocrinology & Metabolism</em>.</li>
 <li>Eastell, R., et al. (2022). "Bone Turnover Markers: Use in the Management of Postmenopausal Osteoporosis." <em>Endocrine Reviews</em>.</li>
 <li>Sniderman, A.D., et al. (2021). "Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review of Emerging Evidence." <em>JAMA Cardiology</em>.</li>
 <li>Matthews, D.R., et al. (1985/Updated 2022). "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man." <em>Diabetologia</em>.</li>
 <li>Maki, P.M., et al. (2021). "The North American Menopause Society (NAMS) Position Statement on Management of Osteoporosis." <em>Menopause</em>.</li>
 </ol>
 </div>
</div>

<script>
function toggleAnswer(id) {
 const el = document.getElementById(id);
 if (el.style.display === 'block') {
 el.style.display = 'none';
 } else {
 el.style.display = 'block';
 }
}

// Standardized listener for any reveal-btn class as well
document.querySelectorAll('.reveal-btn').forEach(button => {
 button.addEventListener('click', function() {
 const answer = this.nextElementSibling;
 if (answer && answer.classList.contains('answer-text')) {
 // The onclick in HTML handles the toggle, but this ensures compatibility
 }
 });
});
</script>
</body>
</html>